HOME - LATEST NEWS - Corporate - Enrollment Completed for 1st Phase 2 Trial for LT3001

LATEST NEWS

Corporate

Corporate

2020.12.04

Enrollment Completed for 1st Phase 2 Trial for LT3001

Lumosa is pleased to announce that the company has completed the #enrollment of its first Phase 2 clinical trial for #LT3001, a new chemical entity for the treatment of acute ischemic stroke. The data is expected to come out in Q1 of 2021.
 
Stroke is one of several diseases that the medical community is trying urgently to resolve. LT3001 has a high expectation not only to replace #rtPA but also to apply to all #AIS patients. Another Phase 2 study adjunct to the endovascular #thrombectomy will be initiated afterwards.
 
#acuteischemicstroke #newdrug #clinicaltrials #humanstudy #phase2